Related Experiment Videos
Radiation enhancement by gemcitabine-mediated cell cycle modulations
Stephan Mose1, Reiner Class, Hans-Walter Weber
1Department of Radiation Oncology, Johann Wolfgang Geothe-University, Grankfurt/Main, Germany.
American Journal of Clinical Oncology
|February 11, 2003
Summary
Gemcitabine (dFdC) enhances radiation therapy effectiveness at low doses by causing cell cycle arrest at the G1/S boundary. This synchronization increases cancer cell sensitivity to radiation, leading to improved cell death.
Area of Science:
- Oncology
- Radiotherapy
- Cell Biology
Background:
- Gemcitabine (2',2'-difluoro-2'-deoxycytidine [dFdC]) is a chemotherapy agent.
- Radiotherapy is a cornerstone of cancer treatment.
- Understanding drug-radiation interactions is crucial for optimizing cancer therapy.
Purpose of the Study:
- To investigate the dose and time dependency of gemcitabine's radiation-enhancing effect.
- To correlate this effect with changes in cancer cell cycle distribution.
- To elucidate the mechanisms underlying gemcitabine's radiosensitizing properties.
Main Methods:
- In vitro experiments using HeLa and #4197 cancer cell lines.
- Fluorometric assays for cell viability after gemcitabine and/or irradiation.
- Flow cytometry and bromodeoxyuridine (BrdU) labeling for cell cycle analysis.
Main Results:
- Gemcitabine enhanced radiation-induced cytotoxicity at low, non-toxic concentrations (<37 nmol/l).
- Gemcitabine induced concentration and time-dependent cell cycle arrest, primarily at the G1/S boundary.
- Radiation caused a G2/M arrest, while gemcitabine synchronized cells at the radiosensitive G1/S phase.
Conclusions:
- Gemcitabine potentiates radiation therapy by arresting cells at the G1/S boundary, enhancing radiosensitivity.
- Low-dose gemcitabine synchronizes cells in a radiosensitive phase, increasing the efficacy of combined treatment.
- The combination of gemcitabine and radiation may induce apoptosis through accumulated cellular stress.